Tenderskhoj
Germany
- Healthcare & Medical Medical
LOCATION SUMMARY DEADLINE
Germany Medicines With The Active Ingredient Rivaroxaban (atc
 30 Apr 2026
Germany Procurement Of Presentation Solutions For District Schools
 11 Jun 2024
Germany Conclusion Not Excluding Drug Discount Agreement. According To § 130a Paragraph. 8 Sgb V By Way Of An Openhouse Model For The Active Ingredient Combination Formoterol/glycopyrronium/budesonide (atccode According To Who
 30 Jun 2025
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Ganirelix (h01cc01) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Estradiol (g03ca03) In The Context Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Paragraph 8 Or 130c Paragraph 1 Sgb V For The Period From 01.07.2024 To 30.06.2026
 06 Jun 2024
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130 A Paragraph. 8 Sgb V With The Active Ingredient Tocilizumab
 11 May 2026
Germany Conclusion Of Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph. 8 Sgb V On The Active Ingredient Rituximab
 11 May 2026
Germany Drug Contracts With An Option To Join
 01 May 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Follitropin Alfa (g03ga05) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026